Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Constantine S. Tam, Tanya Siddiqi, John N. Allan, Thomas J. Kipps, Ian W. Flinn, Bryone Kuss, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Ryan Jacobs, Xavier C. Badoux, Paolo Ghia, Juthamas Sukbuntherng, Ahmed Hamed Salem, Kristin Russell, Karl Eckert, Cathy Zhou, Joi Ninomoto, Danelle F. James, William G. Wierda

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds